Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Weight-loss drug firm becomes Europe’s most valuable

by September 6, 2023
September 6, 2023
Weight-loss drug firm becomes Europe’s most valuable

The maker of weight-loss drug Wegovy has become Europe’s most valuable firm, dethroning the French luxury conglomerate LVMH.

Shares rose after the Danish pharmaceutical giant, Novo Nordisk, launched the popular drug in the UK.

At the close of trading on Monday, the firm had a stock market valuation of $428bn (£339bn).

The drug is now available on the National Health Service in the UK and also on the private market.

Wegovy is an obesity treatment that is taken once a week which tricks people into thinking that they are already full, so they end up eating less and losing weight.

Famous personalities such as Elon Musk are among the reported users of the drug, which has captivated Hollywood and the public more widely since it was approved by regulators in the US in 2021.

Wegovy and Ozempic – a diabetes treatment with similar effects – have been described as “miracle” drugs.

But experts warn the jabs are not a quick fix nor a substitute for a healthy diet and exercise.

In trials, users often put weight back on after stopping treatment.

There has been a global shortage of the jabs so only limited stock arrived for the NHS in the UK on Monday.

The company said it would continue to restrict global supplies as it works to ramp up manufacturing.

Sophie Lund-Yates, lead equity analyst at Hargreaves Lansdown, said that the firm had been “genuinely surprised” by the uptake and said it had been “a victim of its own success”.

“It’s not common that you see a pharmaceutical company so entrenched in popular culture but there are people saying that we need to take a step back and ensure it is being used appropriately and responsibly. Of course, with a lot of fanfare for a drug, you are risking a lot of blowback in the future,” she said.

In the UK, NHS guidelines say patients can only access Wegovy, which contains the drug semaglutide, if they are significantly overweight and have weight-related health problems.

According to the Organisation for Economic Co-operation and Development (OECD), nearly one in three adults are obese in the UK, which is the highest level in Europe.

Last month, a new trial showed Wegovy has also been proven to reduce the risk of a stroke or heart attack.

While the findings still have to be fully reviewed, experts agreed the results were potentially significant.

Read more:
Weight-loss drug firm becomes Europe’s most valuable

0
FacebookTwitterGoogle +Pinterest
previous post
Britain’s school concrete crisis could cost over £150M
next post
Government proposes changes to disability and illness benefits

You may also like

UK wage growth stays strong despite softening labour...

April 15, 2025

Eamonn Holmes loses appeal over tax ruling

March 30, 2023

NatWest to Acquire Sainsbury’s Banking Operations

June 20, 2024

Rachel Reeves urges end to remote working in...

September 23, 2024

Wealthier homeowners hit as banks raise mortgage rates...

May 29, 2025

Fiat Urges Government to Reinstate Electric Car Grants...

February 21, 2024

YouTube is killing ‘Stories’ a popular feature next...

May 26, 2023

British business bank’s start up loans programme unveils...

June 21, 2023

Secrets of Success: Shamanth Pereira, Founder of Something...

March 14, 2024

Investor Pullback in the Fitness Sector: Xponential’s Geisler...

March 14, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • July 30 Event: Senators Tim Kaine and Rand Paul Discuss the Effects of Tariffs on the US Bourbon and Wine Industries

      July 23, 2025
    • Johnson erupts over ‘dangerous’ Biden ‘cover-up’ as Democrats push Epstein disclosure

      July 23, 2025
    • Trump admin official to meet with Israel, Qatar amid push for Gaza ceasefire

      July 23, 2025
    • A Wild Ride For the History Books: 2025 Mid-Year Recap

      July 23, 2025
    • Schumer, Democrats try to save face, blame GOP for possible government shutdown

      July 23, 2025
    • Trump’s approval rating holds steady amid deep partisan divide on deportations and ‘big, beautiful bill’

      July 23, 2025

    Categories

    • Business (8,552)
    • Investing (2,142)
    • Politics (16,170)
    • Stocks (3,224)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved